Popovici Nitu Stoica & Asociatii | View firm profile
First one: Coronavirus & competition – any potential link?
Second one – close related with the first one: Breach of
Competition Law? “Price gouging” or not?
Facts: As a result of the fear generated by the Coronavirus outbreak in Europe in the last past days, the demand for protective masks has risen, including in Romania. The same goes for
the prices… higher and higher…
So? What is this when looking through competition lens? Do we have
a breach of Competition Law? Short answer: Maybe…
When: Let’s see!
The increase of the prices in a crisis is known as “price gouging”
– the increase of prices of goods & services to a level which is deemed to
be unreasonable and unfair.
The feeling of unfairness comes not from the increase in itself,
but from the in which such price increases occur
(e.g., – ) and the products they target – basic necessities.
In some way, price gouging makes us think about pure
In Romania, there are no specific rules which address the issue of
price gouging Nonetheless we have Competition Law and Competition Council (and
Mr. President Bogdan Chiritoiu). In this sense, the Romanian Competition
Council (RCC) did not watch passively the situation regarding the increase of
prices for protective masks and has launched a new investigation. The President
of the Romanian Competition Council has that it is currently investigating the
behaviour of companies which commercialize products & protection equipment
consisting in the sudden and excessive increase of their prices.
Even though the main aim of competition law is to ensure free
competition, competition regulations also protect indirectly consumer welfare.
Having this in mind, if price gouging may be included in one of the categories
sanctioned by competition regulation, then this practice is not fostered from
potential sanctions. At first glance, price gouging may be qualified as an
abuse of dominant position under the form of excessive pricing.
Price gouging has already been under the scrutiny of competition
authorities, especially in the pharmaceutical sector.
At European level, the European Commission has opened with respect to the excessive price
increases concerning five life-saving cancer medicines. This comes after has sanctioned the same
company for excessive pricing concerning some essential off-patent drugs.
In UK, has also
sanctioned a similar deed – excessive prices for anti-epilepsy drugs. However, the
Competition Appeal Tribunal has quashed the CMA’s decision arguing that the CMA
did not prove that the prices practiced were unfair.